Portal de Periódicos da CAPES

Renal Effects of SCH 54470: A Triple Inhibitor of ECE, ACE, and NEP

1997; Wiley; Volume: 15; Issue: 3 Linguagem: Inglês

10.1111/j.1527-3466.1997.tb00335.x

1527-3466

Subbarao Vemulapalli, Madhu Chintala, Andrew W. Stamford, Robert W. Watkins, Pky Chiu, Edmund J. Sybertz, Ahmad Fawzi,

Coagulation, Bradykinin, Polyphosphates, and Angioedema

Cardiovascular Drug ReviewsVolume 15, Issue 3 p. 260-272 Free Access Renal Effects of SCH 54470: A Triple Inhibitor of ECE, ACE, and NEP Subbarao Vemulapalli, Corresponding Author Subbarao Vemulapalli Schering-Plough Research Institute, Kenilworth, NJ 07033Address correspondence and reprint requests to Dr. S. Vemulapalli, Schering-Plough Research Institute, 2015 Galloping Hill Rd., Kenilworth, NJ 07033. Fax: (908) 298-3294.Search for more papers by this authorMadhu Chintala, Madhu Chintala Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorAndrew Stamford, Andrew Stamford Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorRobert Watkins, Robert Watkins Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorPeter Chiu, Peter Chiu Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorEdmund Sybertz, Edmund Sybertz Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorAhmad B. Fawzi, Ahmad B. Fawzi Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this author Subbarao Vemulapalli, Corresponding Author Subbarao Vemulapalli Schering-Plough Research Institute, Kenilworth, NJ 07033Address correspondence and reprint requests to Dr. S. Vemulapalli, Schering-Plough Research Institute, 2015 Galloping Hill Rd., Kenilworth, NJ 07033. Fax: (908) 298-3294.Search for more papers by this authorMadhu Chintala, Madhu Chintala Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorAndrew Stamford, Andrew Stamford Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorRobert Watkins, Robert Watkins Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorPeter Chiu, Peter Chiu Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorEdmund Sybertz, Edmund Sybertz Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorAhmad B. Fawzi, Ahmad B. Fawzi Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this author First published: 02 April 2007 https://doi.org/10.1111/j.1527-3466.1997.tb00335.xCitations: 15AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat REFERENCES 1 Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993– 2000. 2 Bazil MK, Rodney W, Lappe W, Webb RL. Pharmacologic characterization of an endothelinA (ETA) receptor antagonist in conscious rats. J Cardiovasc Pharmacol 1992; 20: 940– 948. 3 Benigni A, Perico N, Gaspari F, et al. Increased renal endothelin production in rats with reduced renal mass. Am J Physiol 1991; 260: F331– F339. 4 Benigni A, Zoja C, Corna D, et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993; 44: 440– 444. 5 Bird JE, Moreland S, Waldron TL, Powell JR. Antihypertensive effects of a novel endothelin-A receptor antagonist in rats. Hypertension 1995; 25: 1191– 1195. 6 Brooks DP, Contino LC, Storer B, Ohlstein EH. Increased endothelin excretion in rats with renal failure induced by partial nephrectomy. Br J Pharmacol 1991; 104: 987– 989. 7 Brooks DP, Depalma D, Gellai M, et al. Nonpeptide endothelin receptor antagonists. III. Effect of SB 209670 and BQ 123 on acute renal failure in anesthetized dogs. J Pharmacol Exp Ther 1994; 271: 769– 775. 8 Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 270: 228– 235. 9 Cole BR, Kuhnline MA, Needleman P. Atriopeptin III. A potent natriuretic, diuretic, and hypotensive agent in rats with chronic renal failure. J Clin Invest 1985; 76: 2413– 2415. 10 Cushman DW, Cheung HS. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 1971; 20: 1637– 1648. 11 Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 1996; 28: 652– 655. 12 Fawzi AB, Cleven R, Wright DL. A rapid and selective endothelin-converting enzyme assay: Characterization of a phosphoramidon-sensitive enzyme from guinea pig lung membrane. Analyt Biochem 1994; 222: 342– 350. 13 Firth JD, Raine AEG, Ratcliffe PJ, Ledingham JGG. Endothelin: An important factor in acute renal failure. Lancet 1988; 2: 1179– 1182. 14 Gellai M, Jugus M, Fletcher, Dewolf R, Nambi P. Reversal of postischemic acute renal failure with a selective endothelinA antagonist in the rat. J Clin Invest 1994; 93: 900– 906. 15 Gellai M, Jugus M, Fletcher T, et al. Nonpeptide endothelin receptor antagonists V: Prevention and reversal of acute renal failure in the rat by SB 209670. J Pharmacol Exp Ther 1995; 275: 200– 206. 16 Heida HS, Gomez-Sanchez CE. Hypoxia increases endothelin release in bovine endothelial cells in culture, but epinephrine, norepinephrine, serotonin, histamine and angiotensin II do not. Life Sci 1990; 47: 247– 251. 17 Ihara M, Noguchi K, Saeki T, et al. Biological profiles of highly potent novel endothelin antagonists selective for ETA receptor. Life Sci 1992; 50: 247– 255. 18 King AJ, Brenner BM, Anderson S. Endothelin: A potent and systemic vasoconstrictor peptide. Am J Physiol 1989; 256: F1051– F1058. 19 Kitamura K, Tanaka T, Kato J, Eto T, Tanaka K. Regional distribution of immunoreactive endothelin in porcine tissue: Abundance in inner medulla of the kidney. Biochem Biophys Res Commun 1989; 161: 348– 352. 20 Kohan D. Endothelin synthesis by rabbit renal tubule cells. Am J Physiol 1991; 261: F221– F226. 21 Kon V, Badar KF. Biological actions and pathophysiological significance of endothelin in the kidney. Kidney Int 1991; 40: 1– 12. 22 Kon V, Yoshioka T, Fogo A, Ichikawa L. Glomerular actions of endothelin in vivo. J Clin Invest 1989; 83: 1762– 1767. 23 Lafferty HM, Gunning M, Silva P, Zimmerman MB, Brenner BM, Anderson S. Enkephalinase inhibition increases plasma atrial natriuretic peptide levels, glomerular filtration rate, and urinary excretion in rats with reduced renal mass. Circ Res 1989; 65: 640– 646. 24 Li JS, Lariviere R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994; 24: 183– 188. 25 Li JS, Schiffrin EL. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension 1995; 25: 495– 500. 26 Lopez-Farre A, Gomez-Garre D, Bernabeu F, Lopez-Hovoa JM. A role for endothelin in the maintenance of post-ischemic renal failure in the rat. J Physiol (London) 1991; 444: 513– 522. 27 Luscher TF, Seo B-G, Bühler FR. Potential role of endothelin in hypertension. Controversy on endothelin in hypertension. Hypertension 1993; 21: 752– 757. 28 McKittrick BA, Stamford AW, Weng X, et al. Design and synthesis of phosphoric acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11. Bioorg Med Chem Lett 1996; 6: 1629– 1634. 29 Mino N, Kobayashi M, Nakajima A, et al. Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats. Eur J Pharmacol 1992; 221: 77– 83. 30 Needleman P, Greenwald J. Atriopeptin: A cardiac hormone intimately involved in fluid, electrolyte, and blood pressure homeostasis. N Engl J Med 1986; 314: 828– 834. 31 Ohlstein EH, Beck GR Jr, Douglas SA, et al. Nonpeptide endothelin receptor antagonist. II. Pharmacological characterization of SB 209670. J Pharmacol Exp Ther 1994; 271: 762– 768. 32 Ohta K, Hirata Y, Shichiri M, et al. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 1991; 39: 307– 311. 33 Orisio S, Benigni A, Bruzzi I, et al. Renal endothelin gene expression is increased in remnant kidney and correlated with disease progression. Kidney Int 1993; 43: 354– 358. 34 Rakuki H, Tubuchi Y, Nakamaru M, et al. Evidence for endothelin-1 release from resistance vessels of rats in response to hypoxia. Biochem Biophys Res Commun 1990; 169: 973– 977. 35 Shibouta Y, Suzuki N, Shino A, et al. Pathophysiological role of endothelin in acute renal failure. Life Sci 1990; 46: 1611– 1618. 36 Smith S, Anderson S, Ballermann BJ, Brenner BM. Role of atrial natriuretic peptide in adaptation of sodium excretion with reduced renal mass. J Clin Invest 1986; 77: 1395– 1398. 37 Sogabe K, Nirei H, Shobo M, et al. Pharmacological profile of FR 139317, a novel, potent endothelin ETA receptor antagonist. J Pharmacol Exp Ther 1993; 264: 1040– 1046. 38 Stewart DJ, Levy RP, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Intern Med 1991; 114: 464– 469. 39 Stockenhuber F, Gottsauner-Wolf M, Marosi L, Liebisch B, Kurz RW, Balcke P. Plasma levels of endothelin in chronic renal failure and after renal transplantation: impact on hypertension and cyclosporin A-associated nephrotoxicity. Clin Sci 1992; 82: 255– 258. 40 Sybertz EJ, Chiu PJS, Vemulapalli S, et al. SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats. J Pharmacol Exp Ther 1989; 250: 624– 631. 41 Tomita K, Naganishi T, Tomura S, et al. Plasma endothelin levels in patients with acute renal failure. N Engl J Med 1989; 324: 1127. 42 Vemulapalli S, Watkins RW, Brown AB, Cook J, Bernardino V, Chiu PJS. Disparate effects of phosphoramidon on blood pressure in SHR and DOCA-salt hypertensive rats. Life Sci 1993; 53: 783– 793. 43 Vemulapalli S, Chiu PJS, Chintala M, Bernardino V. Attenuation of ischemic acute renal failure by phosphoramidon in rats. Pharmacology 1993; 47: 188– 193. 44 Vemulapalli S, Rivelli M, Chiu PJS, Del Prado M, Hey J. Phosphoramidon abolishes the increases in endothelin-1 release induced by ischemia-hypoxia in isolated perfused guinea pig lungs. J Pharmacol Exp Ther 1992; 262: 1062– 1069. 45 Warner TD, Allcock GH, Cordr R, Vane JR. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and release of EDRF. Br J Pharmacol 1993; 110: 777– 782. 46 Wilkes BM, Susin M, Mento PF, et al. Localization of endothelin-like immunoreactivity in rat kidneys. Am J Physiol 1991; 260: F913– F920. 47 Wilkes BM, Susin M, Mento PF, et al. Localization of endothelin-like immunoreactivity in rat kidneys. Am J Physiol 1991; 260: F913– F920. 48 Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411– 415. 49 Yoshida Y, Kawamura T, Ikoma F, Fogo A, Ochikawa I. Effects of antihypertensive drugs on glomerular structure and function in uninephrectomized SHR. Kidney Int 1991; 39: 1112– 1117. Citing Literature Volume15, Issue3September 1997Pages 260-272 ReferencesRelatedInformation